Terms of Access and Use

By downloading, accessing, or viewing material from this website, you agree to the following Terms of Use. The research and analysis provided by Forensic Alpha Limited (“we”, “us”) is for informational and educational purposes only and does not constitute investment advice, a recommendation to buy, sell, or hold any security, or any other form of regulated advice. We do not have, and do not seek to establish, any position (long or short) in the securities discussed in our research.

Our reports present our independent opinions on publicly available information, including but not limited to, company disclosures and financial statements. We aim to highlight potential risks, governance issues, or accounting practices that we believe merit further consideration by market participants. You agree to conduct your own research and due diligence, and to consult your own financial, legal, tax, and other professional advisers before making any investment or business decision. Use of our research is entirely at your own risk. In no event shall Forensic Alpha Limited or any affiliated party be liable for any direct, indirect, incidental, or consequential losses arising from your use of our materials.

The information we provide is based on sources we believe to be accurate and reliable at the time of publication, but it is provided “as is” without any representation or warranty of any kind, whether express or implied, including without limitation as to accuracy, completeness, or fitness for any particular purpose. All opinions expressed are subject to change without notice, and we do not undertake to update or supplement our research.

Access to our research is intended only for persons who are professional investors, institutional investors, or otherwise qualified to receive such information under applicable laws in their jurisdiction. In the United Kingdom, this includes (but is not limited to) persons falling within one or more of the categories described in Articles 19 (Investment Professionals) and 49 (High Net Worth Companies, Unincorporated Associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. By proceeding to access our materials, you confirm that you meet the relevant criteria in your jurisdiction and are legally permitted to receive such information.

All content on this site is the intellectual property of Forensic Alpha Limited and is protected by applicable copyright laws. You agree not to reproduce, distribute, or transmit our research, in whole or in part, without our prior written consent, except by sharing a direct link to our website.

By clicking “I Agree” below, you confirm that you have read and agree to Forensic Alpha Limited’s Terms of Access and Use, that you are a professional or institutional investor (or otherwise qualified under the laws of your jurisdiction to receive such information), and that you understand our research does not constitute investment advice or a recommendation to buy, sell, or hold any security.
I Agree
back arrow

Softcat Plc: 2.5 years later...

Thomas Beevers
Thomas Beevers
May 13, 2026
Copied!
share button icon

Softcat Plc: 2.5 years later...

Softcat originally came onto our radar back in 2022, due to a sharp increase in DSO. Trade receivables had increased by 66% in FY22, and DSO stood at 159 days. At the time, the company explained this was due to a “transient expansion in year-end trade receivables” as a result of implementing a new finance system in Q4 24.

However, since then receivables have not come down. More than 2 years later we can see from the chart below (extracted from our automated report) that DSO remains elevated, and has even crept higher. With the publication of the half-year numbers this week, DSO now stands at 166 days.

Furthermore, our system has now picked up another red flag associated with “unbilled receivables”, which has suddenly grown by over 80% YoY, from £37m to £68m (see extract below). Unbilled receivables represent amounts already recognized as revenues but not yet billed to the client. Because recognition involves a degree of judgement, sharp increases are often associated with aggressive revenue recognition.

Note also the footnote below the table explaining that the increase was “predominantly driven by a specific order where Softcat’s contractual obligation had been fulfilled but was not invoiced to the customer at the period end.” This suggests there was one particularly large customer where the sale was booked just ahead of the period end even though there was no invoice. We are also left wondering why the customer was not invoiced before the period end even through the contractual obligations were fulfilled.

Assuming all of the increase in unbilled receivables was down to this order and assuming a gross margin in line with the group as a whole, if the order hadn’t been booked we calculate the gross profit for H1 (£220m) would have been lower by around £11m. Instead of reporting 12% growth in gross profit and surprising the market on the upside, that growth would only have been 6%.

The simultaneous growth of both trade receivables and unbilled receivables raises a concern around aggressive revenue recognition.  We find it unusual in a sector like this, where the cash cycle should be reasonably short, that there are such high levels of receivables.

These flags are particularly concerning because of the manual process that the company uses to make adjustments to revenue at the period end. The auditor, EY,  raises this in their report as a ‘key audit matter” (see extract below from the FY24 annual report). The report states that the system is ‘susceptible to error’ and relies on notifications from suppliers. They conclude that “there is a risk that revenue is recognised prematurely or fictitiously”. Investors should note that H1 numbers are particularly susceptible to error since they are not subject to an audit.

If you are an institutional investor, you can sign up to our email list here
arrow icon
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Institutional investors are eligible for a 7-day free trial.

Our machine intelligence helps Portfolio Managers to spot critical red flags hidden deep within the financial statements and governance disclosures.

Request Demo

Forensic Alpha uses proprietary machine intelligence to identify risks hidden deep within the financial statements and governance disclosures.

Forensic Alpha Limited
Level 39, One Canada Square
Canary Wharf
London E14 5AB

Forensic Alpha US INC
12 East 49th Street
New York
NY 10017
USA

forensic alpha
Forensic Alpha Limited
Level 39, One Canada Square
Canary Wharf
London E14 5AB
Forensic Alpha US INC
12 East 49th Street
New York NY 10017
USA
Forensic Alpha Limited is authorised and regulated by the Financial Conduct Authority (Reference number: 763770)
© 2022 Forensic Alpha. All rights reserved.  Terms & Conditions  |  Privacy Policy  |  Cookie policy
twitter profilelinkedin profile